Skip to main content

Advertisement

SpringerLink
Log in

Novel titanocene anti-cancer drugs and their effect on apoptosis and the apoptotic pathway in prostate cancer cells

  • Reports
  • Published:
Apoptosis Aims and scope Submit manuscript

Abstract

Advanced prostate cancer is not curable by current treatment strategies indicating a significant need for new chemotherapeutic options. Highly substituted ansa-titanocene compounds have shown promising cytotoxic activity in a range of cancers. The objectives of this study are to examine the effects of these titanocene compounds on prostate cancer cells.

Prostate cell lines were treated with three novel titanocene compounds and compared to titanocene dichloride and cisplatin. Percent apoptosis, viability and cell cycle were assessed using propidium iodide DNA incorporation with flow cytometry. Cytochrome C was assessed by western blotting of mitochondrial and cytoplasmic fractions. Apoptosis Inducing Factor was assessed by confocal microscopy.

These novel compounds induced more apoptosis compared to cisplatin in a dose dependent manner. Compound Y had the most significant effect on cell cycle and apoptosis. Despite the release of cytochrome C from the mitochondrial fraction there was no inhibition of apoptosis with the pan caspase inhibitor, ZVAD-FMK. AIF was shown to translocate from the cytosol to the nucleus mediating a caspase independent cell death. Bcl-2 over expressing PC-3 cells, which were resistant to cisplatin induced apoptosis, underwent apoptosis following treatment with all the titanocene compounds.

This study demonstrates possible mechanisms by which these novel titanocene compounds can mediate their apoptotic effect in vitro. The fact that they can induce more apoptosis than cisplatin in advanced cancer cell lines would confer an advantage over cisplatin. They represent exciting new agents with future potential for the treatment of advanced prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Raghavan D, Koczwara B, Javle M (1997) Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer. Eur J Cancer 33:566–574

    CAS  Google Scholar 

  2. Van Brussel JP, Mickisch GH (2003) Multidrug resistance in prostate cancer. Onkologie 26:175–181

    Article  PubMed  Google Scholar 

  3. Feldman BJ, Feldman D (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1:34–45

    Article  PubMed  CAS  Google Scholar 

  4. Yagoda A, Petrylak D (1993) Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71:1098–1109

    Article  PubMed  CAS  Google Scholar 

  5. Tannock IF, de Wit R, Berry WR, et al(2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512

    Article  PubMed  CAS  Google Scholar 

  6. Loening SA, Beckley S, Brady MF, et al (1983) Comparison of estramustine phosphate, methotrexate and cis-platinum in patients with advanced, hormone refractory prostate cancer. J Urol 129:1001–1006

    PubMed  CAS  Google Scholar 

  7. Köpf-Maier P (1994) Complexes of metals other than platinum as antitumour agents. Eur J Clin Pharmacol 47:1–16

    Article  PubMed  Google Scholar 

  8. Christodoulou CV, Eliopoulos AG, Young LS et al (1998) Anti-proliferative activity and mechanism of action of titanocene dichloride. Br J Cancer 77:2088–2097

    PubMed  CAS  Google Scholar 

  9. Kröger N, Kleeberg UR, Mross K et al (2000) Phase II clinical trial of titanocene dichloride in patients with metastatic breast cancer. Onkologie 23:60–62

    Article  Google Scholar 

  10. Allen OR, Croll L, Gott AL et al (2004) Functionalized cyclopentadienyl titanium organometallic compounds as new antitumor drugs. Organomet 23:288–292.

    Article  CAS  Google Scholar 

  11. Boyles JR, Baird MC, Campling BG, Jain N (2001) Enhanced anti-cancer activities of some derivatives of titanocene dichloride. J Inorg Biochem 84:159–162

    Article  PubMed  CAS  Google Scholar 

  12. Causey PW, Baird MC (2004) Synthesis characterization, and assessment of cytotoxic properties of a series of titanocene dichloride derivatives. Organomet 23:4486–4494

    Article  CAS  Google Scholar 

  13. Meyer R, Brink S, van Rensburg CEJ et al (2005) Synthesis, characterization and antitumor properties of titanocene derivatives with thiophene containing ligands. J Organomet Chem 690:117–125

    Article  CAS  Google Scholar 

  14. Tacke M, Allen LT, Cuffe LP et al (2004) Novel titanocene anti-cancer drugs derived from fulvenes and titanium dichloride. J Organomet Chem 689:2242–2249

    Article  CAS  Google Scholar 

  15. Tacke M, Cuffe LP, Gallagher WM et al (2004) Methoxy-phenyl substituted ansa-titanocenes as potential anti-cancer drugs derived from fulvenes and titanium dichloride. J Inorg Biochem 98:1987–1994

    Article  PubMed  CAS  Google Scholar 

  16. Sweeney N, Mendoza O, Müller-Bunz H et al (2005) Novel benzyl substituted titanocene anti-cancer drugs. J Organomet Chem (in press)

  17. Kelter G, Sweeney NJ, Strohfeldt K et al (2005) In vitro anti-tumor activity studies of bridged and unbridged benzyl-substituted titanocenes. Anti-Cancer Drugs (in press)

  18. Morrissey C, O’Neill A, Spengler B et al (2005) Apigenin drives the production of reactive oxygen species and initiates a mitochondrial mediated cell death pathway in prostate epithelial cells. Prostate 63:131–142

    Article  PubMed  CAS  Google Scholar 

  19. Coffey R, Morrissey C, Taylor C et al (2005) Resistance to caspase dependent hypoxia-induced apoptosis is not HIF-1alpha mediated in androgen independent prostate cancer cells. Cancer 103:1363–1374

    Article  PubMed  CAS  Google Scholar 

  20. Watson RW, Redmond HP, Wang JH, Condron C, Bouchier-Hays D (1996) J. Immunol 156:3986–3992

    PubMed  CAS  Google Scholar 

  21. Penninger JM, Kroemer G (2003) Mitochondria AIF and caspase-rivaling for cell death execution. Nat Cell Biol 5:97–99

    Article  PubMed  CAS  Google Scholar 

  22. Ravagran L, Roumier T, Kroemer G (2002) Mitochandria the killer organelles and their weapons. J Cell Physiol 192:131–137

    Article  Google Scholar 

  23. Bose RN (2002) Biomolecular targets for platinum antitumor drugs. Mini Rev Med Chem 2:103–111

    Article  PubMed  CAS  Google Scholar 

  24. Köpf-Maier P, Krahl D (1981) Intracellular distribution of titanium after treatment with the antitumor agent titanocene dichloride: on electron energy loss spectroscopic study. Naturwissenschaften 68:273–274

    Article  PubMed  Google Scholar 

  25. Köpf-Maier P, Krahl D (1983) Tumor inhibition by metallocenes: ultrastructural localization of titanium and vanadium in treated tumor cells by electron energy loss spectroscopy. Chem Biol Interact 28:317–328

    Article  Google Scholar 

  26. Guo M, Guo Z, Sadler PJ (2001) Titanium(IV) targets phosphoesters on nucleotides: implications for the mechanism of action of the anticancer drug titanocene dichloride. J Biol Inorg Chem 6:698–707

    Article  PubMed  CAS  Google Scholar 

  27. Gonzalez VM, Fuertes MA, Alonso C, Perez JM (2001) Is Cisplatin-induced cell death always produced by apoptosis? Molecular Pharmacology 59:657–663

    PubMed  CAS  Google Scholar 

  28. Perez JM, Montero EI, Gonzalez AM et al (1999) Apoptosis induction and inhibition of H-ras overexpression by novel trans-[PtCl2(isopropylamine)(amine’)] complex. J Inorg Biochem 77:37–42

    Article  PubMed  CAS  Google Scholar 

  29. Zamble DB, Jacks T, Lippard SJ (1998) p53-Dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells. Proc Natl Acad Sci USA 95:6163–6168

    Article  PubMed  CAS  Google Scholar 

  30. Kim R, Emi M, Tanabe T (2005) Caspase-dependent and - independent cell death pathways after DNA damage. Oncol Rep 14:595–599

    PubMed  CAS  Google Scholar 

  31. Park SY, Cho SJ, Kwon HC et al (2004) Caspase-independent cell death by allicin in human epithelial carcinoma cells: involvement of PKA. Cancer Lett 224:123–132

    PubMed  Google Scholar 

  32. Krajewska M, Krajewski S, Epstein JI et al (1996) Immunohistochemical analysis of bcl-2, bax, bcl-x, and mcl-1 expression in prostate cancers. Am J Pathol 148:1567–1576

    PubMed  CAS  Google Scholar 

  33. Cho HJ, Kim JK, Kim KD et al (2005) Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells. Cancer Lett [Epub ahead of print]

Download references

Author information

Authors and Affiliations

  1. UCD School of Medicine and Medical Sciences, Mater Misericordiae University Hospital, Ireland

    K. O'Connor, C. Gill, J. M. Fitzpatrick & R. W. G. Watson

  2. UCD School of Chemistry and Chemical Biology, University College Dublin, Ireland

    M. Tacke, F.-J. K. Rehmann, K. Strohfeldt & N. Sweeney

  3. Conway Institute, University College Dublin and Dublin Molecular Medicine Centre, Ireland

    K. O'Connor, C. Gill, M. Tacke, F.-J. K. Rehmann, K. Strohfeldt, N. Sweeney, J. M. Fitzpatrick & R. W. G. Watson

  4. UCD School of Medicine and Medical Sciences, Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland

    R. W. G. Watson

Authors
  1. K. O'Connor
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Gill
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Tacke
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F.-J. K. Rehmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K. Strohfeldt
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N. Sweeney
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. M. Fitzpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. R. W. G. Watson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. W. G. Watson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

O'Connor, K., Gill, C., Tacke, M. et al. Novel titanocene anti-cancer drugs and their effect on apoptosis and the apoptotic pathway in prostate cancer cells. Apoptosis 11, 1205–1214 (2006). https://doi.org/10.1007/s10495-006-6796-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10495-006-6796-1

Keywords

Search

Navigation